Pharmacoeconomics in COPD and inappropriateness of diagnostics, management and treatment

Respiratory Medicine

Volumn 105, Issue 6, 2011, Pages 828-837

  Donner, Claudio F ^a   Virchow, Johann Christian ^b,c   Lusuardi, Mirco ^d  

^a Mondo Medico   (Italy)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d S Sebastiano Hospital   (Italy)

Author keywords

COPD; Inappropriate management; Pharmacoeconomics; Pulmonary specialist; Social disease

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; INDACATEROL; IPRATROPIUM BROMIDE; PLACEBO; ROFLUMILAST; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ARTICLE; ATTITUDE TO HEALTH; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTINUING EDUCATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ERROR; DIARRHEA; DISEASE COURSE; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH EDUCATION; HUMAN; ITALY; MEDICAL EDUCATION; MEDICAL ERROR; MEDICAL SPECIALIST; OXYGEN THERAPY; PATIENT COMPLIANCE; PHARMACOECONOMICS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCANDINAVIA; SIDE EFFECT; SOCIOPATHY; SPAIN; WEIGHT REDUCTION;

EID: 79955472048     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.12.017     Document Type: Review

References (79)

1. R. Horton The neglected epidemic of chronic disease Lancet 366 2005 1514 (Pubitemid 41540102)
2. R.J. Halbert, J.L. Natoli, A. Gano, E. Badamgarav, A.S. Buist, and D.M. Mannino Global burden of COPD: systematic review and meta-analysis Eur Respir J 28 2006 523 532 (Pubitemid 44794666)
3. D. Mannino Chronic obstructive pulmonary disease in 2025: where are we headed? Eur Respir J 26 2005 189 (Pubitemid 41079059)
4. I. Annesi-Maesano Epidemiology of chronic obstructive pulmonary disease Eur Respir Mon 38 2006 41 70
5. D.E. O'Donnell, S. Aaron, J. Bourbeau, P. Hernandez, D. Marciniuk, M. Balter, G. Ford, A. Gervais, R. Goldstein, R. Hodder, F. Maltais, J. Road Canadian Thoracic Society Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease Can Respir J 10 Suppl. A 2003 11A 65A (Pubitemid 36986735)
6. M. Lusuardi, F. Blasi, C. Terzano, C. Cricelli, N. Crispino, L. Comarella, F. De Benedetto, C.M. Sanguinetti, L. Allegra, and C.F. Donner Standards of care and clinical predictors in patients hospitalised for a COPD exacerbation - The Italian SOS (Stratification Observational Study) Monaldi Arch Chest Dis 71 4 2009 153 160
7. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of COPD (update 2009) Medical Communications Resources, Inc, 2009. http://www.goldcopd.org
8. G. Viegi, S. Maio, F. Pistelli, S. Baldacci, and L. Carrozzi Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution Respirology 11 2006 523 532 (Pubitemid 44186256)
9. J. Balmes, M. Becklake, P. Blanc, P. Henneberger, K. Kreiss, C. Mapp, D. Milton, D. Schwartz, K. Toren, G. Viegi Environmental and Occupational Health Assembly, American Thoracic Society American thoracic society statement: occupational contribution to the burden of airway disease Am J Respir Crit Care Med 167 2003 787 797
10. S.S. Salvi, and P.J. Barnes Chronic obstructive pulmonary disease in non-smokers Lancet 29 374 2009 733 743
11. J.B. Varkey, A.B. Varkey, and B. Varkey Prophylactic vaccinations in chronic obstructive pulmonary disease: current status Curr Opin Pulm Med 15 2009 90 99
12. R. De Marco, S. Accordini, I. Cerveri, A. Corsico, J.M. Antó, N. Künzli, C. Janson, J. Sunyer, D. Jarvis, S. Chinn, P. Vermeire, C. Svanes, U. Ackermann-Liebrich, T. Gislason, J. Heinrich, B. Leynaert, F. Neukirch, J.P. Schouten, M. Wjst, and P. Burney Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm Am J Respir Crit Care Med 175 2007 32 39 (Pubitemid 46105306)
13. 1/FVC < 70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes Thorax 63 2008 1040 1045
14. W.M. Vollmer, T. Gíslason, P. Burney, P.L. Enright, A. Gulsvik, A. Kocabas, and A.S. Buist Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study Eur Respir J 34 2009 588 597
15. 1/FVC ratio reduces the misclassification of airway obstruction Thorax 63 2008 1046 1051
16. M. Weatherall, J. Travers, P.M. Shirtcliffe, S.E. Marsh, M.V. Williams, M.R. Nowitz, S. Aldington, and R. Beasley Distinct clinical phenotypes of airways disease defined by cluster analysis Eur Respir J 34 2009 812 818
17. ATS/ERS Standards for the diagnosis and management of patients with COPD Available at: http://www.thoracic.org/COPD/ accessed 01.06.2010
18. P.J. Barnes, and B.R. Celli Systemic manifestations and co-morbidities of COPD Eur Respir J 33 2009 1165 1185
19. D.P. Tashkin, B. Celli, M. Decramer, D. Liu, D. Burkhart, C. Cassino, and S. Kesten Bronchodilator responsiveness in patients with COPD Eur Respir J 31 2008 742 750
20. ® studies Int J Chron Obstruct Pulmon Dis 4 2009 185 201
21. M. Cazzola, F. Di Marco, P. Santus, B. Boveri, M. Verga, M.G. Matera, and S. Centanni The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD Pulm Pharmacol Ther 17 2004 35 39 (Pubitemid 37468407)
22. T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, T. Polanowski, and R. Kessler Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 180 2009 741 750
23. B. Celli, M. Decramer, I. Leimer, U. Vogel, S. Kesten, and D.P. Tashkin Cardiovascular safety of tiotropium in patients with COPD Chest 137 1 2010 20 30
24. L.P. McGarvey, M. John, J.A. Anderson, M. Zvarich, R.A. Wise TORCH Clinical Endpoint Committee Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee Thorax 62 2007 411 415 (Pubitemid 46698390)
25. C. Crim, P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, P.W. Jones, L.R. Willits, J.C. Yates, and J. Vestbo Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Eur Respir J 34 2009 641 647
26. L.M. Fabbri, P.M. Calverley, J.L. Izquierdo-Alonso, D.S. Bundschuh, M. Brose, F.J. Martinez, K.F. Rabe M2-127 and M2-128 study groups Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials Lancet 374 2009 695 703
27. M. Osthoff, and J.D. Leuppi Management of chronic obstructive pulmonary disease patients after hospitalization for acute exacerbation Respiration 79 2010 255 261
28. J.R. Hurst, G.C. Donaldson, J.K. Quint, J.J. Goldring, R. Baghai-Ravary, and J.A. Wedzicha Temporal clustering of exacerbations in chronic obstructive pulmonary disease Am J Respir Crit Care Med 179 2009 369 374
29. 1: an intricate tango Respiration 77 2009 229 235
30. M.A. Puhan, M. Scharplatz, T. Troosters, and J. Steurer Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality: a systematic review Respir Res 6 2005 54
31. Nocturnal Oxygen Therapy Trial Group Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial Ann Intern Med 93 1980 391 398
32. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party Lancet 1 1981 681 686
33. National Collaborating Centre for Chronic Conditions Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care Thorax 59 Suppl. 1 2004 1 232
34. T.E. Eaton, C. Grey, and J.E. Garret An evaluation of short-term oxygen therapy: the prescription of oxygen to patients with chronic lung disease hypoxic at discharge from hospital Respir Med 95 2001 582 587 (Pubitemid 32624523)
35. A. Fishman, F. Martinez, K. Naunheim, S. Piantadosi, R. Wise, A. Ries, G. Weinmann, D.E. Wood National Emphysema Treatment Trial Research Group A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema N Engl J Med 348 2003 2059 2073 (Pubitemid 36583301)
36. L. Nici, C. Donner, E. Wouters, R. Zuwallack, N. Ambrosino, J. Bourbeau, M. Carone, B. Celli, M. Engelen, B. Fahy, C. Garvey, R. Goldstein, R. Gosselink, S. Lareau, N. MacIntyre, F. Maltais, M. Morgan, D. O'Donnell, C. Prefault, J. Reardon, C. Rochester, A. Schols, S. Singh, and T. Troosters ATS/ERS Pulmonary Rehabilitation Writing Committee. American thoracic Society/European respiratory society statement on pulmonary rehabilitation Am J Respir Crit Care Med 173 2006 1390 1413 (Pubitemid 43900715)
37. A. Buist, M. McBurnie, W. Vollmer, S. Gillespie, P. Burney, D.M. Mannino, A.M. Menezes, S.D. Sullivan, T.A. Lee, K.B. Weiss, R.L. Jensen, G.B. Marks, A. Gulsvik, E. Nizankowska-Mogilnicka BOLD Collaborative Research Group International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study Lancet 370 2007 741 750 (Pubitemid 47321907)
38. Life and breath: respiratory disease in Canada 2007 Public Health Agency of Canada http://www.phac-aspc.ca
39. N. Mittmann, L. Kuramoto, S. Seung, J.M. Haddon, C. Bradley-Kennedy, and J.M. Fitzgerald The cost of moderate and severe COPD exacerbations to the Canadian healthcare system Respir Med 102 2008 413 421
40. K. Chapman, J. Bourbeau, and L. Rance The burden of COPD in Canada: results from the confronting COPD survey Respir Med 97 2003 23 31
41. J. Bourbeau, R. Sebaldt, A. Day, J. Bouchard, A. Kaplan, P. Hernandez, M. Rouleau, A. Petrie, G. Foster, L. Thabane, J. Haddon, and A. Scalera Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study Can Respir J 15 2008 13 19 (Pubitemid 351575058)
42. S.D. Aaron, K.L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. Balter, D. O'Donnell, A. McIvor, S. Sharma, G. Bishop, J. Anthony, R. Cowie, S. Field, A. Hirsch, P. Hernandez, R. Rivington, J. Road, V. Hoffstein, R. Hodder, D. Marciniuk, D. McCormack, G. Fox, G. Cox, H.B. Prins, G. Ford, D. Bleskie, S. Doucette, I. Mayers, K. Chapman, N. Zamel, M. FitzGerald Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial Ann Intern Med 146 2007 545 555 (Pubitemid 351650535)
43. M. Najafzadeh, C.A. Marra, M. Sadatsafavi, S.D. Aaron, S.D. Sullivan, K.L. Vandemheen, P.W. Jones, and J.M. Fitzgerald Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD Thorax 63 2008 962 967
44. R.S. Goldstein, E.H. Gort, G.H. Guyatt, and D. Feeny Economic analysis of respiratory rehabilitation Chest 112 1997 370 379 (Pubitemid 27349426)
45. H. Rea, S. McAuley, A. Stewart, C. Lamont, P. Roseman, and P. Didsbury A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease Intern Med J 34 2004 608 614 (Pubitemid 39587142)
46. Chronic Obstructive Pulmonary Disease Axis of Respiratory Health Network, Fonds de recherche en santé du Québec F. Maltais, J. Bourbeau, S. Shapiro, Y. Lacasse, H. Perrault, M. Baltzan, P. Hernandez, M. Rouleau, M. Julien, S. Parenteau, B. Paradis, R.D. Levy, P. Camp, R. Lecours, R. Audet, B. Hutton, J.R. Penrod, D. Picard, and S. Bernard Effects of homebased pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial Ann Intern Med 149 2008 869 878
47. N. Clark, J. Dodge, M. Partridge, and F.J. Martinez Focusing on outcomes: making the most of COPD interventions Int J Chron Obstruct Pulmon Dis 4 2009 61 77
48. J. Bourbeau, J. Collet, K. Schwartzman, T. Ducruet, D. Nault, and C. Bradley Economic benefits of self-management education in COPD Chest 130 2006 1704 1711 (Pubitemid 46033422)
49. W. Rosser, J. Colwill, J. Kasperski, and L. Wilson Patient-centered medical homes in Ontario N Engl J Med 362 2010 e7
50. National Heart, Lung, and Blood Institute Morbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases http://www.nhlbi.nih.gov/ resources/docs/2009-ChartBook.pdf accessed 18.01.2010
51. T.L. Croxton, and W.C. Bailey Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report Am J Respir Crit Care Med 174 2006 373 378 (Pubitemid 44223116)
52. A.O. D'Souza, M.J. Smith, L.A. Miller, and J. Kavookjian An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD Chest 129 2006 1693 1708 (Pubitemid 43895002)
53. D.E. Hilleman, N. Dewan, M. Malesker, and M. Friedman Pharmacoeconomic evaluation of COPD Chest 118 2000 1278 1285
54. A. Jubran, N. Gross, J. Ramsdell, R. Simonian, K. Schuttenhelm, M. Sax, D.J. Kaniecki, R.J. Arnold, and F.A. Sonnenberg Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-center study Chest 103 1993 678 684 (Pubitemid 23086156)
55. D.A. Sclar, R.F. Legg, T.L. Skaer, L.M. Robison, and N.L. Nemic Ipratropium bromide in the management of chronic obstructive pulmonary disease: effect on health service expenditures Clin Ther 16 1994 595 601 (Pubitemid 24321689)
56. M. Friedman, C.W. Serby, S.S. Menjoge, J.D. Wilson, D.E. Hilleman, and T.J. Witek Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD Chest 115 1999 635 641 (Pubitemid 29129937)
57. P.W. Jones, K. Wilson, and S. Sondhi Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation Respir Med 97 2003 20 26 (Pubitemid 36104894)
58. J.G. Ayres, M.J. Price, and J. Efthimiou Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial Respir Med 97 2003 212 220 (Pubitemid 36266876)
59. D.D. Sin, K. Golmohammadi, and P. Jacobs Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity Am J Med 116 2004 325 331 (Pubitemid 38230292)
60. Y. Oba Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD Am J Manag Care 15 2009 226 232
61. A. Briggs, H. Glick, G. Lozano-Ortega, M. Spencer, P.M. Calverley, P. Jones, and J. Vestbo Towards a revolution in COPD health (TORCH) investigators. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Eur Respir J 35 2010 532 539
62. A.A. Dalal, H. Petersen, L. Simoni-Wastila, and C.M. Blanchette Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 mug/salmeterol 50 mug combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD J Med Econ 12 2009 339 347
63. A.A. Dalal, L. Christensen, F. Liu, and A.A. Riedel Direct costs of chronic obstructive pulmonary disease among managed care patients Int J Chron Obstruct Pulmon Dis 5 2010 341 349
64. M. Miravitlles, J.B. Soriano, F. García-Río, L. Muñoz, E. Duran-Taulería, G. Sánchez, V. Sobradillo, and J. Ancochea Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities Thorax 64 2009 863 868
65. M. Miravitlles, C. Murio, T. Guerrero, R. Gisbert on behalf of the DAFNE study group Costs of chronic bronchitis and COPD. A one year follow-up study Chest 123 2003 784 791 (Pubitemid 36315494)
66. J.F. Masa, V. Sobradillo, C. Villasante, C.A. Jiménez-Ruiz, L. Fernández-Fau, J.L. Viejo, and M. Miravitlles Costs of chronic obstructive pulmonary disease in Spain: estimation from a population-based study Arch Bronconeumol 40 2004 72 79 (Pubitemid 38339278)
67. J.L. Izquierdo-Alonso, and J. de Miguel-Díez Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease J COPD 1 2004 215 223
68. L. Bildea, A.R. Svenninga, J. Dollerup, H.B. Borgeskov, and P. Lange The cost of treating patients with COPD in Denmark - a population study of COPD patients compared with non-COPD controls Respir Med 101 2007 539 546 (Pubitemid 46196322)
69. R. Dal Negro, P. Berto, S. Tognella, and L. Quareni Global outcomes in lung disease study Group. Cost-of-illness of lung disease in the TriVeneto region, Italy: the GOLD study Monaldi Arch Chest Dis 57 2002 3 9 (Pubitemid 34873733)
70. R. Dal Negro, A. Rossi, and I. Cerveri The burden of COPD in Italy: results from the confronting COPD survey Respir Med 97 Suppl. C 2003 S43 S50
71. R. Dal Negro Optimizing economic outcomes in the management of COPD Int J Chron Obstruct Pulmon Dis 3 2008 1 10 (Pubitemid 351523714)
72. R.W. Dal Negro, S. Tognella, R. Tosatto, M. Dionisi, P. Turco, and C.F. Donner Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes) Respir Med 102 2008 92 101 (Pubitemid 350161843)
73. R.W. Dal Negro, L. Bonadiman, C. Turati, and P. Turco Clinical and pharmacoeconomic profile of COPD patients with FEV1 50-60% predicted: pilot study on the impact of the extended indication of ICS/LABA Ther Adv Respir Dis 3 2009 51 58
74. www.who.int/respiratory/gard
75. S. Nardini Schiarire l'aria: uno studio nazionale sulla bronco pneumopatia cronica ostruttiva Multidiscip Respir Med 2 1 2007 19 22 www.healthcarecommission.gov.uk
76. F. De Benedetto, C.F. Donner, S. Nardini, and C.M. Sanguinetti La Bpco, la medicina respiratoria e i cambiamenti in corso nell'assistenza sanitaria Multidisciplinary Respir Med 2 1 2007 13 15
77. D. Blumenthal Stimulating the adoption of health information technology N Engl J Med 360 2009 1477 1479
78. European Commission Competitiveness and innovation framework programme (CIP). The 2008-2011 European patients smart open services project (epSOS) ESF Sci Policy Brief 35 2008 1 10 European Science Foundation. Advancing Systems Biology for Medical Applications www.epsos.eu9
79. R.A. Mularski, S.M. Asch, and W.H. Shrank The quality of obstructive lung disease care for adults in the United States as measured by adherence to recommended processes Chest 130 2006 1844 1850 (Pubitemid 46033444)